12th Biennial Graylyn Conference on Women's Cognitive Health

描述(由申请人提供)：治疗和预防妇女特有的疾病是一个关键的研究领域，涵盖了从分子到社会、行为和经济终点的所有方法。这种广泛的科学努力正被用来确定女性发生的与年龄相关的认知变化，并确定防止女性认知能力下降的最有效方法。不同学科之间以及基础、临床和卫生服务科学家之间的互动将导致旨在增强认知健康的最有效的翻译干预。维克森林大学健康科学(WFUHS)妇女健康研究、领导和教育卓越中心(WHCoE)于1995年开始每年召开妇女健康格雷林会议，并于1997年设立两年一次的关于妇女认知健康的格雷林会议，以进行与妇女健康有关的前沿认知研究。2007年格雷林妇女认知健康会议探讨了激素治疗的具体问题，以及与妇女认知老化有关的更广泛的问题。自那次会议以来，临床和基础科学研究继续致力于更好地了解妇女健康倡议记忆研究(WHIMS)和妇女健康倡议认知老龄化研究(WHISCA)所取得的成果，并更充分地探索旨在解决妇女与年龄相关的认知功能障碍等更广泛复杂问题的新方法。我们计划通过将于2009年举行的题为“通过创新的翻译研究改善妇女认知老龄化的轨迹”的第十二次格雷林会议，在妇女认知健康领域的领导人之间继续这一关键和不断发展的对话。受邀的演讲者将介绍并批判性地回顾从基础研究到临床研究和卫生服务研究的当前知识，以指导制定关于荷尔蒙和其他与提高女性认知老化知识相关的疗法的创新研究议程的努力。与以往一样，这次会议的规模将相对较小(约100人参加)，演讲者将提供主题领域的尖端科学演讲。会议的重点将是从长椅到床边再到社区政策和实践的研究，并将重点放在翻译上。将讨论如何加强包括多个学科的翻译对话，并确定在分子、动物、人体研究和社区推广以及循证医学实践层面上研究女性认知老化的主要方向。 公共卫生相关性：在女性中，认知老化是一个严重的问题，对个人、她的家庭以及巨大的经济影响都有社会影响。增进我们对与认知老化相关的问题的理解将有助于解决这一日益增长的担忧。这次会议使来自世界各地不同学科的研究人员能够通过开发新的机制来检测认知能力下降并开发有希望的治疗方法来解决这个问题，这些治疗方法可能会延缓与痴呆症相关的症状的发生和发展。

DESCRIPTION (provided by applicant): The treatment and prevention of diseases that are unique to women is a critical area of research that encompasses the entire spectrum of approaches from molecular to social, behavioral and economic endpoints. This breadth of scientific endeavors is being used to determine the age-related cognitive changes that occur in women and to identify the most effective approaches to prevent cognitive decline in women. Interactions among disciplines and between basic, clinical and health services scientists will lead to the most efficacious translational interventions designed to enhance cognitive health. The Women's Health Center of Excellence for Research, Leadership, Education (WHCoE) of the Wake Forest University Health Sciences (WFUHS) began annual Graylyn Conferences of Women's Health in 1995 and in 1997 established the biennial Graylyn Conferences on Women's Cognitive Health for cutting-edge cognitive research related to women's health. The 2007 Graylyn Conference on Women's Cognitive Health explored issues specific to hormone therapy (HT) and broader issues related to women's cognitive aging. Since that meeting, clinical and basic science research has continued the goal of better understanding the results obtained in the Women's Health Initiative Memory Study (WHIMS) and the Women's Health Initiative Study of Cognitive Aging (WHISCA) and more fully exploring novel approaches designed to address the broader complex questions of age-related cognitive dysfunction in women. We plan to continue this critical and evolving dialogue among leaders in the field of women's cognitive health through the12th Graylyn Conference to be held in 2009 entitled "Improving the Trajectory of Cognitive Aging in Women through Innovative Translational Research". Invited speakers will present and critically review the current knowledge from basic to clinical research and health services research in order to guide efforts toward developing an innovative research agenda about hormonal and other therapies relevant to the advancement of knowledge in women's cognitive aging. As in the past, this conference will be relatively small (about 100 attendees) with speakers providing cutting-edge scientific presentations in themed areas. The emphasis of conference sessions will be on research from bench to bedside to community policy and practice with a translational focus. Discussions will be on how to enhance translational dialogues that include multiple disciplines, and on identifying the key directions for research on women's cognitive aging at the molecular, animal, human studies, and community outreach and practice of evidence-based medicine levels. PUBLIC HEALTH RELEVANCE: Among women, cognitive aging is a critical concern that has social impact on the individual, her family, as well as an enormous economic impact. Enhancing our understanding of the problems associated with cognitive aging would assist in addressing this growing concern. This conference enables investigators from various disciplines worldwide to tackle the problem by developing new mechanisms to detect cognitive decline and develop promising treatments that may delay the onset and progression of the symptoms associated with dementia.